Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07060794 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tafenoquine and ACTs (TADORE- Plus)

Study acronym: TADORE+
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title revisedv3
  2. Enrollment target: 280 to 507v2 Show 4 more changesShow less
    • Start date: Nov 2025 to Jun 2026
    • Primary and study completion dates: Dec 2027 to Jun 2028
    • Interventions: Tafenoquine (Drug) to Tafenoquine plus Artesunate-pyronaridine (Drug), Tafenoquine plus DHA-Piperaquine (Drug)
    • Study arms: 2 to 3
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up (delayed radical cure).
Trial Details
NCT Number NCT07060794
Lead Sponsor Menzies School of Health Research
Conditions
(from sponsor)		 Vivax Malaria
Related terms Malaria, Vivax
Enrollment 507 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov